Rybelsus

Adolescent Obesity

PfizerPhase 2/3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 95/ 100

Competitive context

574 Active assets in the Adolescent Obesity cohort.

Asset / Sponsor	Phase	Rating
vi-0521 VIVUS LLC	Phase 4	BBB
Tirzepatide LABORATORIOS INDUFAR	Phase 4	BBB
Phentermine Russell McCulloh, MD	Phase 4	BBB
asc30 Ascletis Pharma (China) Co., Limited	Phase 2	BBB
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 4	BBB

View all 50 →

Same molecule, other indications

Rybelsus is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant

BB

Indicative ·

68 / 100

polycystic ovary syndromeDormant

B

Indicative ·

60 / 100

diabetes mellitusDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.